Mirum Pharmaceuticals Completes $268.6 Million Acquisition of Bluejay Therapeutics to Strengthen Rare Disease Pipeline

Pharmaceutical Executive January 26, 2026
Nicholas Jacobus

Key Takeaways

• Mirum Pharmaceuticals acquired Bluejay Therapeutics, gaining a late-stage liver disease program and potential entry into the HDV treatment market.
• HDV is a severe coinfection with hepatitis B, affecting 230,000 people in the US and Europe, with high mortality rates.
• Brelovitug, a monoclonal antibody in Phase III trials, has shown promising results in Phase II studies for HDV treatment.
• Mirum plans a biologics license application submission in 2027, contingent on trial outcomes, and secured $268.5 million in financing.

Mirum Pharmaceuticals’ acquisition of Bluejay Therapeutics adds brelovitug to its pipeline, positioning the company for a potential first approved treatment for chronic hepatitis delta virus while reinforcing its focus on late-stage rare liver disease development.

Mirum Pharmaceuticals announced the...

Today's Sponsors

Today's Sponsor